The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients

Sponsor
University Health Network, Toronto
Study ID
NCT05938712
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Kidney Transplant Recipients

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The study aims to determine the short-term efficacy, mechanisms and safety of 12 weeks of dapagliflozin and semaglutide combination therapy in 20 KTR, with and without T2D.

Key Dates

Start date
Oct 24, 2023
Status verified
Apr 2026
Primary completion
Oct 1, 2027
Completion
Mar 1, 2028

Study Design

Enrollment
20 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Semaglutide
    Semaglutide Subcutaneous 0.25mg once weekly for 4 weeks, then 0.5mg once weekly for 4 weeks, then 1mg once weekly for 4 weeks.
  • Experimental: Dapagliflozin
    Dapagliflozin Tablets Total Dose 10mg daily for 12 weeks

Primary Outcome Measure

Proximal tubular natriuresis with combination therapy [ Time Frame: From baseline to combination therapy end (24 weeks) ]

Central Contacts

Related Studies